Septerna Inc (SEPN)

$5.80 -0.09 (-1.53%)
Market Cap 261.53M
Revenue (ttm) 151,000.00
Net Income (ttm) 4.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 375.50%
Debt to Equity Ratio 0.00
Volume 1,170,800
Avg Vol 572,534
Day's Range N/A - N/A
Shares Out 44.40M
Stochastic %K 18%
Beta N/A
Analysts Strong Sell
Price Target $25.67

Latest News on SEPN

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Feb 21, 2025, 10:00 AM EST - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Feb 20, 2025, 10:00 AM EST - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Feb 19, 2025, 2:00 PM EST - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 4:15 PM EST - 4 days ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Feb 18, 2025, 8:00 AM EST - 4 days ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 8:00 AM EST - 2 months ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 20, 2024, 7:00 AM EST - 3 months ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Nov 19, 2024, 2:10 PM EST - 3 months ago

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 30, 2024, 4:41 PM EDT - 4 months ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Oct 26, 2024, 1:30 AM EDT - 4 months ago

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

INGM LBGJ PRB ROLR SAG SNYR

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 25, 2024, 12:25 PM EDT - 4 months ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 9:47 PM EDT - 4 months ago

Septerna Prices Upsized Initial Public Offering

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Oct 24, 2024, 8:11 AM EDT - 4 months ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Biotech Septerna aims to raise up to $186 million in US IPO

Oct 21, 2024, 6:26 AM EDT - 4 months ago

Biotech Septerna aims to raise up to $186 million in US IPO

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

Oct 7, 2024, 11:36 AM EDT - 4 months ago

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

Septerna IPO Registration Document (S-1)

Oct 2, 2024, 4:22 PM EDT - 5 months ago

Septerna IPO Registration Document (S-1)